Literature DB >> 30155838

Evaluation of Biliary Bacterial Resistance in Patients with Frequent Biliary Instrumentation, One Size Does Not Fit All.

Maen Masadeh1, Subhash Chandra2, Daniel Livorsi3, Frederick Johlin1, William Silverman4,5.   

Abstract

BACKGROUND: Bacteremia due to cholangitis can occur as a complication of biliary instrumentation. Biliary sepsis can result from frequent endoscopic retrograde cholangiopancreatography (ERCP).
METHODS: We hypothesized that routine use of antibiotics in patients who require frequent ERCPs leads to cholangitis resistant to empiric antibiotics used to treat biliary sepsis. We retrospectively reviewed patients with frequent biliary instrumentation and blood stream infection due to cholangitis. Conventional empiric antibiotics were defined as broad-spectrum antibacterial agents predominantly used for community-acquired infections and surgical prophylaxis. Broad-spectrum antibacterial agents used for hospital-onset/multidrug-resistant infections were defined as broad-spectrum MDR antibiotics.
RESULTS: Seventy-eight patients had bacteremia secondary to cholangitis from biliary obstruction. Over 50% of bacteria were not sensitive to conventional empiric antibiotics for biliary sepsis. Thirty-seven patients did not receive post-procedural antibiotics and forty-one patients did. Of the ones who did, 58% later had a bloodstream infection with bacteria resistant to the antibiotic used for prophylaxis, and 26 patients (63%) required a broad-spectrum MDR antibiotic for treatment. The number of ERCPs was not associated with resistance to prophylactic antibiotics (p 0.7103) or needing broad-spectrum MDR antibiotics for treatment of cholangitis-associated bacteremia (p 0.1868). Routine use of antibiotic prophylaxis after ERCP was associated with trend toward need for broad-spectrum MDR antibiotics for cholangitis-associated bacteremia, Chi-square 3.7, 0 0.0540.
CONCLUSION: Bacterial resistance to conventional empiric antibiotics is an emerging problem. Blood cultures are needed to guide therapy.

Entities:  

Keywords:  Antibiotics; Ascending cholangitis; Biliary sepsis; ERCP

Mesh:

Substances:

Year:  2018        PMID: 30155838     DOI: 10.1007/s10620-018-5263-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.

Authors:  A Kaneko; J Sasaki; M Shimadzu; A Kanayama; T Saika; I Kobayashi
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

2.  In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus.

Authors:  Natsuo Yamamoto; Jiro Fujita; Takashi Shinzato; Futoshi Higa; Masao Tateyama; Masato Tohyama; Isamu Nakasone; Nobuhisa Yamane
Journal:  Int J Antimicrob Agents       Date:  2006-01-18       Impact factor: 5.283

Review 3.  Antibiotic prophylaxis for GI endoscopy.

Authors:  Mouen A Khashab; Krishnavel V Chithadi; Ruben D Acosta; David H Bruining; Vinay Chandrasekhara; Mohamad A Eloubeidi; Robert D Fanelli; Ashley L Faulx; Lisa Fonkalsrud; Jenifer R Lightdale; V Raman Muthusamy; Shabana F Pasha; John R Saltzman; Aasma Shaukat; Amy Wang; Brooks D Cash
Journal:  Gastrointest Endosc       Date:  2014-11-11       Impact factor: 9.427

4.  Antibiotic prophylaxis for infectious complications after therapeutic endoscopic retrograde cholangiopancreatography: a randomized, double-blind, placebo-controlled study.

Authors:  B Byl; J Devière; M J Struelens; I Roucloux; A De Coninck; J P Thys; M Cremer
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

5.  Antibiotic prophylaxis of infectious complications with endoscopic retrograde cholangiopancreatography. A randomized controlled study.

Authors:  G Sauter; B Grabein; G Huber; G A Mannes; G Ruckdeschel; T Sauerbruch
Journal:  Endoscopy       Date:  1990-07       Impact factor: 10.093

6.  Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis.

Authors:  Rungsun Rerknimitr; Evan L Fogel; Cem Kalayci; Edward Esber; Glen A Lehman; Stuart Sherman
Journal:  Gastrointest Endosc       Date:  2002-12       Impact factor: 9.427

7.  Resistant pathogens in biliary obstruction: importance of cultures to guide antibiotic therapy.

Authors:  Michael J Englesbe; Lillian G Dawes
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

8.  Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: results of a randomized controlled clinical study.

Authors:  C Niederau; U Pohlmann; H Lübke; L Thomas
Journal:  Gastrointest Endosc       Date:  1994 Sep-Oct       Impact factor: 9.427

9.  Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes.

Authors:  M Melzer; R Toner; S Lacey; E Bettany; G Rait
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 10.  Acute Bacterial Cholangitis.

Authors:  Vincent Zimmer; Frank Lammert
Journal:  Viszeralmedizin       Date:  2015-06-11
View more
  2 in total

Review 1.  Duodenoscope-associated infection prevention: A call for evidence-based decision making.

Authors:  Cori L Ofstead; Brandy L Buro; Krystina M Hopkins; John E Eiland; Harry P Wetzler; David R Lichtenstein
Journal:  Endosc Int Open       Date:  2020-11-17

2.  Surgical Antimicrobial Prophylaxis in Abdominal Surgery for Neonates and Paediatrics: A RAND/UCLA Appropriateness Method Consensus Study.

Authors:  Sonia Bianchini; Erika Rigotti; Sara Monaco; Laura Nicoletti; Cinzia Auriti; Elio Castagnola; Giorgio Conti; Luisa Galli; Mario Giuffrè; Stefania La Grutta; Laura Lancella; Andrea Lo Vecchio; Giuseppe Maglietta; Nicola Petrosillo; Carlo Pietrasanta; Nicola Principi; Simonetta Tesoro; Elisabetta Venturini; Giorgio Piacentini; Mario Lima; Annamaria Staiano; Susanna Esposito
Journal:  Antibiotics (Basel)       Date:  2022-02-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.